Spain Minimal Residual Disease Testing Market Size & Outlook

The minimal residual disease testing market in Spain is expected to reach a projected revenue of US$ 96.0 million by 2030. A compound annual growth rate of 10.9% is expected of Spain minimal residual disease testing market from 2025 to 2030.
Revenue, 2024 (US$M)
$50.3
Forecast, 2030 (US$M)
$96.0
CAGR, 2025 - 2030
10.9%
Report Coverage
Spain

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Spain minimal residual disease testing market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

Spain minimal residual disease testing market highlights

  • The Spain minimal residual disease testing market generated a revenue of USD 50.3 million in 2024 and is expected to reach USD 96.0 million by 2030.
  • The Spain market is expected to grow at a CAGR of 10.9% from 2025 to 2030.
  • In terms of segment, flow cytometry was the largest revenue generating technology in 2024.
  • Next Generation Sequencing (NGS) is the most lucrative technology segment registering the fastest growth during the forecast period.


Minimal residual disease testing market data book summary

Market revenue in 2024USD 50.3 million
Market revenue in 2030USD 96.0 million
Growth rate10.9% (CAGR from 2025 to 2030)
Largest segmentFlow cytometry
Fastest growing segmentNext Generation Sequencing (NGS)
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationFlow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Technology
Key market players worldwideExact Sciences Corp, Illumina Inc, Natera Inc, Guardant Health Inc, Roche, Foundation Medicine, Qiagen NV, Veracyte Inc, MDxHealth SA, Bio-Techne Corp


Other key industry trends

  • In terms of revenue, Spain accounted for 2.1% of the global minimal residual disease testing market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany minimal residual disease testing market is projected to lead the regional market in terms of revenue in 2030.
  • Germany is the fastest growing regional market in Europe and is projected to reach USD 255.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Minimal Residual Disease Testing Market Companies

Name Profile # Employees HQ Website
MDxHealth SA View profile - - -
Veracyte Inc View profile - - -
Foundation Medicine View profile 251-500 Cambridge, Massachusetts, United States, North America http://www.foundationmedicine.com
Roche View profile 10001+ Basel, Basel-Stadt, Switzerland, Europe http://www.roche.com
Bio-Techne Corp View profile 3050 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 https://www.bio-techne.com
Natera Inc View profile 3293 13011 McCallen Pass, Building A Suite 100, Austin, TX, United States, 78753 https://www.natera.com
Exact Sciences Corp View profile 6600 5505 Endeavor Lane, Madison, WI, United States, 53719 https://www.exactsciences.com
Guardant Health Inc View profile 1779 3100 Hanover Street, Palo Alto, CA, United States, 94304 https://www.guardanthealth.com
Qiagen NV View profile 5900 Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL https://www.qiagen.com
Illumina Inc View profile 9300 5200 Illumina Way, San Diego, CA, United States, 92122 https://www.illumina.com

Spain minimal residual disease testing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to minimal residual disease testing market will help companies and investors design strategic landscapes.


Flow cytometry was the largest segment with a revenue share of 46.72% in 2024. Horizon Databook has segmented the Spain minimal residual disease testing market based on flow cytometry, polymerase chain reaction (pcr), next generation sequencing (ngs), other technology covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Spain minimal residual disease testing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Spain minimal residual disease testing market databook

  • Our clientele includes a mix of minimal residual disease testing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Spain minimal residual disease testing market , including forecasts for subscribers. This country databook contains high-level insights into Spain minimal residual disease testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Spain minimal residual disease testing market report size, by technology, 2018-2030 (US$M)

Spain Minimal Residual Disease Testing Market Outlook Share, 2024 & 2030 (US$M)

Spain minimal residual disease testing market report size, by technology, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online